

Summit Speakers & Discussants



September 13: Welcome Remarks



Victor J. Dzau is the President of the US National Academy of Medicine (NAM). In addition, he serves as Vice Chair of the US National Research Council. He is Chancellor Emeritus and James B. Duke Professor of Medicine at Duke University and the past President and CEO of the Duke University Health System. Previously, Dr. Dzau was the Hersey Professor of Medicine and Chairman of Medicine at Harvard Medical School's Brigham and Women's Hospital, as well as Bloomfield Professor and Chairman of Medicine at Stanford University.

He is an internationally acclaimed leader and scientist has made a significant impact through his seminal research in cardiovascular medicine and genetics. His important work on the renin angiotensin system paved the way for the contemporary understanding of cardiovascular disease. He pioneered gene therapy for vascular disease and was the first to introduce DNA decoy molecules to block transcription as gene therapy in humans. His pioneering research in cardiovascular regeneration led to the Paracrine Hypothesis of stem cell action and the therapeutic strategy of direct cardiac reprogramming.

At the National Academies, Dr Dzau has designed and led important initiatives such as the Commission on a Global Health Risk Framework for the Future; the Human Genome Editing Initiative; the Vital Directions for Health and Health Care, and the Action Collaborative on Countering the U.S. Opioid Epidemic. The NAM Global Grand Challenge for Healthy Longevity represents his vision to inspire across disciplines and sectors to coalesce around a shared priority and audacious goal to advance health.



September 13: Welcome Remarks



Dr. William N. Hait leads the external sourcing and creation of transformational innovation to help Johnson & Johnson achieve its mission to change the trajectory of health for humanity. He works on building an enterprise-wide external R&D pipeline, creating innovative solutions that utilize J&J's excellence in pharmaceuticals, medical devices and consumer products. His team strives to identify disruptive technologies and cuttingedge early innovations in disease areas of emphasis at J&J, to eliminate disease through prevention, interception and cures.

Dr. Hait joined J&J in 2007 and served as Global Therapeutic Area Head for Oncology from 2009 to 2011, and then as Global Head, Janssen Research & Development, from 2011 through 2018. Before that, he was the founding Director of The (Rutgers) Cancer Institute of New Jersey.From 1993 to 2007 he was Professor of Medicine and Pharmacology and Associate Dean for Oncology Programs at the University of Medicine and Dentistry of New Jersey -- Robert Wood Johnson Medical School.

Dr. Hait joined the Yale University School of Medicine faculty in 1984 and became Associate Professor of Medicine and Pharmacology, Chief of the Division of Medical Oncology, Associate Director of the Yale University Comprehensive Cancer Center, Director of the Breast Cancer Unit and Co-Director of the Lung Cancer Unit. He is Board Certified in Internal Medicine and Medical Oncology.

He devoted time to numerous advisory and editorial boards, served in a range of scientific functions, societies and committees, was elected President of the American Association for Cancer Research (2007 – 2008) and has received numerous awards and honors.



Terry Fulmer, PhD, RN, FAAN, is President of The John A. Hartford Foundation in New York City, a national philanthropy dedicated to improving the care of older adults. She serves as the chief strategist for the Foundation and her vision for better care of older adults is catalyzing the Age-Friendly Health Systems social movement. She is an elected member of the National Academy of Medicine and recently served on the independent Coronavirus Commission for Safety and Quality in Nursing Homes. She previously served as Dean of Health Sciences at Northeastern University and Founding Dean of the New York University College of Nursing. Dr. Fulmer is nationally and internationally recognized as a leading expert in geriatrics and is also known for conceptualization and development of the national NICHE program and research on the topic of elder abuse and neglect. She is the first nurse to have served on the board of the American Geriatrics Society. She is also the first nurse to have served as President of the Gerontological Society of America, which awarded her the 2019 Donald P. Kent Award for exemplifying the highest standards for professional leadership in the field of

aging.



September 13: Vision and Opportunities



Dr. James C. Liao, currently serves as the President of Academia Sinica, Taiwan. He is an elected Member of the US National Academy of Engineering, US National Academy of Sciences, and Academician of Academia Sinica in Taiwan. Dr. Liao, a pioneer in Metabolic Engineering and Synthetic Biology, received his BS degree from National Taiwan University and PhD from University of Wisconsin-Madison. After working as a research scientist at Eastman Kodak Company, Rochester, NY, he started his academic career at Texas A&M University in 1990 and moved to UCLA in 1997. He received numerous awards and recognitions, including the US EPA Presidential Green Chemistry Challenge Award (2010), the White House "Champion of Change" for innovations in renewable energy (2012), the ENI Renewable Energy Prize bestowed by the President of Italy, and the US National Academy of Sciences Award for the Industrial Application of Science (2014).



Chen Wang, M.D., Ph.D., is the President of Chinese Academy of Medical Sciences and Peking Union Medical College. He has long been engaged in the clinical practice, research and teaching of respiratory medicine and has special expertise in pulmonary embolism, pulmonary hypertension, respiratory failure, pulmonary heart disease, chronic obstructive pulmonary diseases (COPD, Chronic Bronchitis Emphysema), new respiratory infectious diseases and tobacco epidemiology. He has contributed many important innovations, including the development of thrombolysis therapy and sequential mechanical ventilation, both of which have been added to international treatment guidelines. He oversees multiple national research projects and international programs.



Kurt Hoeller, MBA, Since December 2015, Kurt is Director of Business Creation and member of the Executive Management Team at EIT Health, one of the largest healthcare initiatives worldwide with 150 leading organizations spanning key areas of healthcare such as Pharma, MedTech, Payers, Research Institutions and Universities. Kurt is leading the EIT Health Accelerator having supported more than 1000 startups with close access to all leading players in health industry. Currently, Kurt is also acting as Co-Managing Director of EIT Health Services and Investment GmbH, the commercial arm of EIT Health e.V. Within Innolife, the preparation consortium of EIT Health, Kurt was part of the Executive Committee as a spokesperson for all German academic partners.

From 2009 to 2015, Kurt has been the founding director of the Central Institute of Healthcare Engineering (ZIMT) at Friedrich-Alexander-University (FAU). Since then, he has gone on to found and direct several other spin-offs and companies: CiNNAMED GmbH (2013, CEO and co-founder), Portabiles GmbH (2014, CFO and co-founder), and HOELLER ELECTRONIC GmbH (CEO in 2015). Since May 2015 he has been a member of the city council in Erlangen and member (vice-chairman since July 2020) of the supervisory board of ESTW AG, a company with almost 200mio€ annual revenue and 500+ employees.



September 13: Vision and Opportunities



Dr. John W. R. Phillips serves as Chief of the Population and Social Processes Branch of the NIA Division of Behavioral and Social Research. During a career spanning over 20 years, John has worked to produce research and data resources

on aging related topics. Prior to joining BSR in 2018, John was Associate Commissioner for Research, Evaluation, and Statistics at the US Social Security Administration, leading one of the 13 principal federal statistical agencies charged with producing research and data to inform policy-makers and the public about the nation's retirement and disability programs. He previously served in other research roles in the federal government including Health Scientist Administrator for NIA, as well as Research Economist and Director of the Office of Policy Research at SSA.

His research examined aging issues ranging from retirement security, intergenerational transfers, and distributional effects of retirement and disability programs. Both his pre-doctoral research and his post-doctoral fellowship at the University of Pennsylvania were supported by NIA. John's current area of emphasis at NIA are the economics of aging and the development of international comparators to the US Health and Retirement Study to support aging research. John received a PhD in Economics from Syracuse University.



Professor Tan Chorh Chuan was appointed as the inaugural Chief Health Scientist and concurrently, Executive Director of the new Office for Healthcare Transformation in Singapore's Ministry of Health with effect from 1 January 2018. Prof Tan was President of the National University of Singapore from 2008 to 2017. He has served in senior leadership roles in the healthcare and biomedical sciences sectors including as Chairman of the National University Health System from 2011-18, and Deputy Chairman of ASTAR from 2004 to 2018. A renal physician-scientist, Prof Tan obtained his medical training at NUS, and research training at the Institute of Molecular Medicine, University of Oxford. He is the first Singaporean to be elected as an international member of the US National Academy of Medicine



George MacGinnis leads the £98 million research and innovation programme supporting the UK Government's Ageing Society Grand Challenge to ensure that people can enjoy at least 5 extra healthy, independent years of life by 2035, while narrowing the gap between the experience of the richest and poorest.
He has a varied background in health and care innovation including recent work on the future capacity needs for a reformed health and social care system in the Republic of Ireland, a review of the impact on the NHS of Small Business Research Initiative in Healthcare, a landscape review of the MedTech sector for the Academic Health Science Networks and leading the user group for a global industry alliance to enable a consumer-friendly market for digital wellness and health products and services through standards and accreditation.



September 13: Visionary Keynote Robert Langer



Robert Langer is one of 12 Institute Professors at the Massachusetts Institute of Technology (MIT); being an Institute Professor is the highest honor that can be awarded to a faculty member. He has written over 1,500 articles, which have been cited over 350,000 times; his h-index of 292 is the highest of any engineer in history and tied for the 4th highest of any individual in any field. His patents have licensed or sublicensed to over 400 companies; he is a cofounder of a number of companies including Moderna. Dr Langer served as Chairman of the FDA's Science Board (its highest advisory board) from 1999-2002. His over 220 awards include both the United States National Medal of

Science and the United States National Medal of Technology and Innovation (he is one of 3 living individuals to have received both these honors), the Charles Stark Draper Prize (often called the Engineering Nobel Prize), Queen Elizabeth Prize for Engineering, Albany Medical Center Prize, Breakthrough Prize in Life Sciences, Kyoto Prize, Wolf Prize for Chemistry, Millennium Technology Prize, Priestley Medal (highest award of the American Chemical Society), Gairdner Prize, and the Dreyfus Prize in Chemical Sciences. He holds 36 honorary doctorates and has been elected to the National Academy of Medicine, the National Academy of Engineering, the National Academy of Sciences and the National Academy of Inventors.



September 14: Visionary Keynote Eric Verdin



Eric Verdin, M.D., is the President and Chief Executive Officer of The Buck Institute for Research on Aging. A native of Belgium, Dr. Verdin received his Doctorate of Medicine (M.D.) from the University of Liege and additional clinical and research training at Harvard Medical School. He has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Picower Institute for Medical Research. Dr. Verdin is also a Professor of Medicine at UCSF. Dr. Verdin has published more than 210 scientific papers and holds more than 15 patents. He is a highly cited scientist (top one percent) and has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging and a senior scholarship from the Ellison Medical Foundation. He is an elected member of several prestigious scientific organizations including the American Association for the Advancement of Science, the American Society for Clinical Investigation and the Association of American Physicians. He serves on the Advisory Council of NIDA at the National Institutes of Health.

September 14: Spotlight & Discussion with Catalyst Awardees



Dr. James C. Liao, currently serves as the President of Academia Sinica, Taiwan. He is an elected Member of the US National Academy of Engineering, US National Academy of Sciences, and Academician of Academia Sinica in Taiwan. Dr. Liao, a pioneer in Metabolic Engineering and Synthetic Biology, received his BS degree from National Taiwan University and PhD from University of Wisconsin-Madison. After working as a research scientist at Eastman Kodak Company, Rochester, NY, he started his academic career at Texas A&M University in 1990 and moved to UCLA in 1997. He received numerous awards and recognitions, including the US EPA Presidential Green Chemistry Challenge Award (2010), the White House "Champion of Change" for innovations in renewable energy (2012), the ENI Renewable Energy Prize bestowed by the President of Italy, and the US National Academy of Sciences Award for the Industrial

Application of Science (2014).





cell function in the context of tissue regeneration, diseases, and aging. Nir Barzilai, Professor of Medicine and Genetics and Director of the biggest



Center in the world to study the Biology of Aging and the principal investigator of the Einstein Nathan Shock Center and the Glenn center. He was the recipient of an NIH Merit Award aiming to extend the healthy life span in rodents by biological interventions. He also studied families of centenarians that have provided genetic/biological insights on the protection against aging. Several drugs are developed based, in part, on these paradigm-changing studies. Dr. Barzilai is the author of over 280 peerreviewed papers and a recipient of numerous prestigious awards, including the recipient of the 2010 Irving S. Wright Award of Distinction in Aging Research and is the 2018 recipient of the IPSEN Longevity award. He am leading the TAME (Targeting/Taming Aging with Metformin) multi central study to prove that concept that multi morbidities of aging can be delayed in interventions. He is on the board of AFAR, its scientific director and a founding member of the Academy for Lifespan and Health span. He also cofounded CohBar and Lifebiosciences.

Tom Cheung is the S H Ho Associate Professor of Life Science in the Division of Life Science at the Hong Kong University of Science and Technology (HKUST). He is a skilled and accomplished stem cell scientist and research on the biology of stem cell aging. The main focus of the Cheung laboratory at HKUST is to specify the molecular pathways that control stem cell guiescence and stem cell-mediated tissue regeneration to achieve a better understanding of somatic stem



and the private sector to reimagine the second half of life. He is a

Globa



Shelia Cotten, a sociologist, is the Associate Vice President for Research Development and a Provost's Distinguished Professor at Clemson University. She has joint faculty appointments in the Sociology, Anthropology and Criminal Justice Department and the Department of Communication. Her research examines technology use across the life course, and the health, social, educational, and workforce impacts of technology use. Much of her research has focused on the digital divide and digital inequalities, with a special emphasis on helping older adults to successfully use emerging technologies to enhance their health and quality of life. Her current research focuses on perceptions, use, and impacts of emerging technologies – such as autonomous vehicles, wearables, and smart homes. Her research has been funded by the National Institute on Aging, the National Science Foundation, and other organizations.





Michele J. Grimm, Ph.D., is the Wielenga Creative Engineering Endowed Professor of Mechanical Engineering at Michigan State University. She is a Fellow of the American Society of Mechanical Engineers, the Biomedical Engineering Society, and the American Institute of Medical and Biological Engineering. Dr. Grimm completed her B.S. in Biomedical Engineering and Engineering Mechanics at The Johns Hopkins University in 1990 and her Ph.D. in Bioengineering at the University of Pennsylvania in 1994. For the past 25 years, a significant portion of her research has involved injury biomechanics – from characterizing important tissue properties to developing appropriate models for the assessment of injury mechanisms. She recently finished a 3-year rotation as a program director at the National Science Foundation, overseeing the Biomechanics and Mechanobiology, Engineering of Biomedical Systems, and Disability & Rehabilitation Engineering Programs. During this time, she served as co-chair of the White House's Office of Science & Technology Policy (OSTP) Task Force on Research and Development for Technology to Support Aging Adults.

Jutta Treviranus is the director of the Inclusive Design Research Centre (IDRC), which she founded in 1993. The mission of the centre is to proactively ensure that emerging technical systems and associated practices are designed inclusively. She is also a professor at OCAD University in Toronto where she established a graduate program in inclusive design. Dr. Treviranus is the Head of the Inclusive Design Institute a multi-organization centre of expertise, and the Co-Director of Raising the Floor International. Jutta is credited with developing an inclusive design methodology that has been adopted by large enterprise companies such as Microsoft, as well as public digital services such as the Canadian Digital Service.





Thomas A. Rando, MD, PhD is a Professor in the Department of Neurology and Neurological Sciences at the Stanford University School of Medicine. Dr. Rando is the founding director of the Glenn Center for the Biology of Aging at Stanford University, and he is the Deputy Director of the Stanford Center on Longevity. He is the Program Director for an NIA-funded training program in aging research for graduate students and postdoctoral fellows at Stanford.
Dr. Rando's research focuses on stem cell biology and the biology of aging. He has been a pioneer in the field of systemic factors as regulators of cellular aging beginning with seminal studies done in his laboratory using the technique of heterochronic parabiosis. These studies have formed the foundation of current approaches to epigenetic rejuvenation. He is a scientific founder of Fountain Therapeutics whose mission is to develop therapies for diseases of aging based these fundamental biological principles.



Felipe Sierra, PhD. After training as a biochemist in his native Chile, he obtained a PhD in Biochemistry and Molecular Biology from the University of Florida in 1983.
After working in Switzerland (University of Geneva and then Nestlé) for 10 years, he returned to Academia at the Medical College of Pennsylvania, and later at the Lankenau Institute for Medical Research in Pennsylvania, a position concomitant with a primary appointment at the University of Chile in Santiago. In 2002, Dr. Sierra relocated again to the US, this time as Program Director within the Division of Aging Biology, NIA. He became the Director of this unit in April 2006, until his retirement in April 2020. At that time he took a leadership position in Toulouse, France, as Director for Geroscience in the Inspire Program. Together with Dr. Ron Kohanski, Dr. Sierra was also the co-founder and co-leader of the trans-NIH GeroScience Interest Group (GSIG). The group seeks to promote research on the "geroscience hypothesis" which states that slowing the rate of aging will delay the initiation or diminish the severity of adult-onset diseases and loss-of-resilience. He has received multiple recognitions for this work, including twice the NIH Director's Awards, a BEACON Award and a Career Achievement Award from the American Aging



Paul Irving is chairman of the Milken Institute Center for the Future of Aging, chairman of Encore.org, and distinguished scholar-in-residence at the University of Southern California Davis School of Gerontology. He previously served as the Milken Institute's president, an advanced leadership fellow at Harvard University, and chairman and CEO of Manatt, Phelps & Phillips, LLP, a national law and consulting firm.

Irving is a member of the Global Advisory Council of the Stanford University Distinguished Careers Institute, the Board of Councilors of the USC Davis School, the Global Coalition on Aging Advisory Council, the Advisory Board of WorkingNation, and the National Academy of Medicine Commission for Healthy Longevity. He also serves as a director and chair of East West Bancorp, Inc. and on the International Strategic Committee of the Quadrivio Group Silver Economy Fund. Irving previously served on the Bipartisan Policy Center Senior Health and Housing Task Force and as a participant in the 2015 White House Conference on Aging. Author/editor of "The Upside of Aging: How Long Life Is Changing the World of

and contributor to the Harvard Business Review, PBS NextAvenue, and Forbes.





Kaushik Sunder Rajan is Professor of Anthropology and Co-Director, Chicago Center for Contemporary Theory at the University of Chicago. He works on the global political economy of the life sciences and biomedicine, with an empirical focus on India, South Africa and the United States. He is the author of Biocapital: The Constitution of Postgenomic Life (2006), Pharmocracy: Value, Politics and Knowledge in Global Biomedicine (2017), and Multisituated: Ethnography as Diasporic Praxis (2021). He is currently embarked on a research project that studies the intersections between health, law and constitutionalism in South Africa.





Dr. Xinxin (Katie) Zhu is a clinician and health informatics professional with substantial experience in health management, biomedical informatics research, advisory and consulting. She brings multidisciplinary experience to her current role as the Executive Director of the Center for Biomedical Data Science at School of

Medicine, Yale University. In addition to her medical training and practice in anesthesiology, she also received her M.S. in Computer Science from Rensselaer Polytechnic Institute and Ph.D. in Biomedical Informatics from Columbia University through the U.S. National Library of Medicine Informatics Training Fellowship. Prior to joining Yale faculty, Dr. Zhu served as an External Advisory Board member to the Center for Advanced Technology at Columbia University, physician scientist lead at

the Center for Computational Health at IBM Watson Research, Chief Medical Information Officer at Kforce Government Solutions, associate medical director at Pfizer, clinical project manager at Philips, and healthcare subject matter expert at the

U.S. Department of Veterans Affairs. She is the recipient of many excellence awards, and author of numerous scientific publications and 13 granted patents, as well as co-editor for an Elsevier book on Digital Health. Dr. Zhu has served as Co-Chair for the American Medical Informatics Association's Global Health Informatics

Working Group, VP of Membership for the Consumer and Pervasive Health Informatics Working Group, as well as Scientific Program and Women Leadership Committee members. She is the Co-Chair for the International Medical Informatics Association's Organizational and Social Issues in Healthcare Working Group. She was elected to the fellowship of the American Medical Informatics Association, and the International Academy of Health Sciences Informatics.

Majd Alwan, Ph.D., a noted researcher and authority on aging-services technologies, is LeadingAge's senior vice president of technology, and executive director of the LeadingAge Center for Aging Services Technologies (CAST). Dr. Alwan leads a network of technology companies, providers and research institutions focused on technology solutions for an aging society. Prior to joining CAST, Majd served as an Assistant Professor and the Director of the Robotics and Eldercare Technologies Program at the University of Virginia's Medical Automation Research Center. Majd has a Ph.D. in intelligent robotics from Imperial College of Science, Technology and Medicine, University of London; a Master's of Science degree in control engineering with distinction from Bradford University; and a bachelor's degree in electrical engineering from Damascus University.



September 22: Visionary Keynote Mehmood Khan



Mehmood Khan, MD, is Chief Executive Officer of Hevolution Foundation, a first-of-its-kind non-profit organization that will target grants and early-stage investments to incentivize healthspan science across disciplines and borders for the benefit of all. Prior to joining Hevolution, Dr. Khan served as Chief Executive Officer and Board Member of Life Biosciences Inc., which focuses on advancing scientific research and developing innovative new therapies to improve and extend healthy lives for everyone. In his role as CEO, Dr. Khan provided strategic direction and operational oversight across Life Biosciences and its six daughter companies, pursuing his vision of a more efficient and effective drug development pathway that will drive innovation in the science and technology Life Biosciences advances. Before his role at Life Biosciences, Dr. Khan previously served as Vice

Chairman and Chief Scientific Officer of Global Research and Development at PepsiCo, a Fortune 50 company employing upwards of 250,000 employees across 22 brands. At PepsiCo, Dr. Khan played

a pivotal role in the company's global R&D efforts to create breakthrough innovations in food, beverages, and nutrition, including the incorporation of healthier and more nutritious offerings across its portfolio. Dr. Khan also oversaw PepsiCo's global sustainability initiatives based on the belief that success in business is inextricably linked to the sustainability of the world we share.





Marcia C. Haigis is a Professor in the Department of Cell Biology at Harvard Medical School where she is also the Director of Gender Equity for Faculty in Science. She obtained her Ph.D. in Biochemistry from the University of Wisconsin and performed postdoctoral studies at MIT studying mitochondrial metabolism. In 2018 Dr. Haigis was selected for the National Academy of Medicine Emerging Leaders in Health and Medicine Program. She has contributed to our understanding of how mitochondria contribute to aging and age-associated diseases, such as cancer. Her studies have uncovered new metabolic vulnerabilities in cancer, including identifying new nodes of fat utilization and elucidating the metabolic recycling of ammonia to generate amino acids important for tumor growth.



Dr. Satchin Panda is a Professor at The Salk Institute in La Jolla, California where his lab performs basic and translational research into links between circadian rhythms, chronic disease, and health. His lab has shown that lifestyle or drug interventions that promote robust circadian rhythms can be used to prevent, manage, and even reverse a wide range of chronic diseases, thereby promoting healthy aging. Major areas of his research that are directly relevant to the biology of healthy longevity including the following: 1. His discovery of a blue light sensor in the retina has driven changes in the way we light the built environment to optimize sleep, mood, and brain function.

2. He discovered that eating within a consistent 8-12 hours each day, called time-restricted eating or intermittent fasting, can prevent or reverse chronic diseases and increase the healthy lifespan.

3. His circadian genomics studies in primates have shown that most FDAapproved drugs should be administered at a specific time of day to improve efficacy and minimize adverse side effects.

4. Finally, his lab, along with others, has demonstrated that drugs targeting components of the circadian clock have widespread health benefits and can potentially be used to treat chronic diseases, such as liver disease, cancer, and Alzheimer's disease.



John (Jack) Rowe, Ph.D., A geriatrician/ gerontologist, I chair the Research Network on an Aging Society. I am a long term NAM member and in the past have served as Professor of Medicine and founding Director of the Division on Aging at Harvard Medical School, President of the Mount Sinai School of Medicine and Medical Center and CEO of Aetna.





Sharon K. Inouye, MD, MPH, is an internationally recognized leader in clinical medicine and research. She is Professor of Medicine at Harvard Medical School and Director of the Aging Brain Center at the Marcus Institute for Aging Research, Hebrew SeniorLife. She is board-certified in internal medicine (geriatrics), and expert in public health, health policy, and epidemiology. She developed a scientifically proven method for reducing delirium in hospitalized older persons, the Hospital Elder Life Program (HELP), implemented in hundreds of hospitals worldwide. She created the Confusion Assessment Method (CAM), translated into >20 languages, and used in over 10,000 publications to date. She has dedicated her career to serving vulnerable populations; her clinical practice includes geriatric and homeless populations.







Gilda A. Barabino, is President of the Olin College of Engineering. She previously served as the Daniel and Frances Berg Professor and Dean of Engineering at The City College of New York's (CCNY) Grove School of Engineering. Prior to joining CCNY, she served as Associate Chair for Graduate Studies and Professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory. At Georgia Tech she also served as the inaugural Vice Provost for Academic Diversity. Prior to Georgia Tech and Emory, she rose to the rank of Full Professor of Chemical Engineering and served as Vice Provost for Undergraduate Education at Northeastern University. She is a noted investigator in the areas of sickle cell disease, cellular and tissue engineering, and the role of race/ethnicity and gender in science and engineering, the National Academy of Medicine and the American Academy of Arts and Sciences. She chairs the National Academies Committee on Women in Sciences, Engineering and Medicine and is President-elect of the American Association for the Advancement of Science. She received her B.S. degree in Chemistry from Xavier University of Louisiana and her Ph.D. in Chemical Engineering from Rice University.

Dykki Settle has more than 25 years of experience in leadership and development of digital technology, data systems, and their enabling environments in more than 20 countries and global organizations. Mr. Settle is currently PATH's Chief Digital Officer and Director of PATH's Center of Digital and Data Excellence, setting digital transformation strategy for the organization and leading more than 90 staff to deliver an unparalleled global portfolio of digital and data projects and investments. Mr. Settle also serves in several global technical leadership capacities. He serves as a Commissioner on the Lancet/Financial Times 'Governing Health Futures 2030' Commission, and as co-Chair of the Transform Health coalition, exploring the convergence of digital health, artificial intelligence (AI) and other frontier technologies with universal health coverage (UHC) to support attainment of the third Sustainable Development Goal (SDG).





Dr. David C. Rhew is the Global Chief Medical Officer (CMO) & VP of Healthcare for Microsoft. He is Adjunct Professor at Stanford University; holds six U.S. technology patents that enable authoring, mapping, and integration of clinical decision support into electronic health records; and has been recognized as one of the 50 most influential clinical executives by Modern Healthcare. Dr. Rhew received his Bachelors of Science degrees in computer science and cellular molecular biology from University of Michigan. He received his MD degree from Northwestern University and completed internal medicine residency at Cedars-Sinai Medical Center. He completed fellowships in health services research at Cedars-Sinai and infectious diseases at the University of California, Los Angeles.

Dr. Hiroki Nakatani has held academic positions in Japan at Keio University Faculty of Medicine and Osaka University Post Graduate School of Medicine. He also serves in various national and international organizations as Chair, Board of Directors, Global Health Innovative Technology Fund (GHIT Fund); Senior-Advisor, Economic Research Institute for ASEAN and East Asia (ERIA) ; Member, Board of Directors, National Center for Global Health and Medicine; and Director, Human Resource Strategy Center for Global Health. He is a veteran public health specialist for over 40 years, who started his career at the Ministry of Health, Labour, and Welfare in Japan. He worked extensively in health policy, public health, international health, and health science and technology. From March 2007 to May 2015, he served as Assistant Director-General of WHO, leading the largest technical cluster of HIV/AIDS, Tuberculosis, Malaria, and Neglected Tropical Diseases. After he retired from WHO, Dr.Nakatani has continued to serve the Organization as a member of the Executive Board and various oversight and advisory committees.





Linda Fried, M.D., MPH, A world-renowned geriatrician and epidemiologist, Dr. Fried has led ongoing innovation across her career toward the goals of healthy longevity and successful societies of longer lives. These innovations include substantial scientific advancements in defining frailty as a medical syndrome and its causes; leading multiple major NIH-funded populationbased studies to determine the definition, causes, consequences and prevention of frailty, chronic diseases, multimorbidity, loneliness, and disability in aging. Dr. Fried is the co-designer and co-founder of the Experience Corps, a ground-breaking model for senior volunteerism designed to deploy the social capital of older volunteers to support children's elementary school success and to promote the health of the older volunteers, now in 23 US cities under the auspices of AARP, and in multiple countries.

Dr. Fried has proposed that the creation of healthy longevity and new societal institutions could transform the potential of longer lives into a Third Demographic Dividend where all ages and societies flourish. She serves as co-chair of the National Academy of Medicine's 2019-2022 Global Commission on a Global Roadmap for Healthy Longevity, an initiative that will make strategic recommendations from the realms of public health, medicine, science, and technology towards these goals.





Dr. Joon Yun is President and Managing Partner of Palo Alto Investors, LP, a hedge fund founded in 1989 with approximately \$2 billion in assets invested in healthcare. Board certified in radiology, Joon served on the clinical faculty at Stanford from 2000-2006. Joon has served on numerous boards, and he is currently a trustee of the Salk Institute. Joon and his wife Kimberly launched the \$1 million Palo Alto Longevity Prize and donated \$2 million to support the National Academy of Medicine's Longevity Grand Challenge. He received his M.D. from Duke Medical School and B.A. from Harvard College.





Holm Keller serves as Executive Chairman of KENUP Foundation, a global partnership in innovation, promoting research-based innovation for the public and societal benefit. Previously, for 10 years, Mr. Keller held the elective public office as Chancellor and Executive Vice President for University Development and Innovation at Leuphana University in Germany.

Prior to his public service work, he worked as President Asia for Bertelsmann Inc. in Shanghai, Seoul and Sydney after holding topmanagement positions with the media-group in Gütersloh, London and New York. Before, Holm Keller served a consultant with McKinsey & Company Inc., where he co-lead the development of the Firm's global Accelerator Practice. Earlier in his career, he held operative functions with ARD. ZDF and arte television.

Originally trained as a musical composer, Keller holds degrees from Vienna University and Harvard's Kennedy School of Government.

September 22: Accelerator Awards



Murray McKinnon, Ph.D., As Global Head of the World Without Disease Accelerator (WWDA), Murray leads a team focused on catalyzing a paradigm shift from disease care to health care through novel approaches to prevention, interception and cure. Murray's work is driven by a vision to create a world without disease and stop, reverse or inhibit an individual's progression to disease. Murray previously served as Global Head, Immunosciences, WWDA, where he led the development of a portfolio of WWDA therapeutic interventions, based on immunomodulation, mechanisms of chronic inflammation, and nutritional and drug discovery platforms, to better understand early-disease initiating events and ultimately develop novel therapies to prevent, intercept or cure disease. With over 30 years of industry experience in global pharmaceutical roles, Murray brings a wealth of knowledge and expertise in drug discovery and early development, with a track record of driving scientific innovation in internal programs and through external partnerships. In his ten-year tenure at Janssen, Murray was Head of Immunology Discovery, responsible for leading global teams to identify



Holm Keller serves as Executive Chairman of KENUP Foundation, a global partnership in innovation, promoting research-based innovation for the public and societal benefit. Previously, for 10 years, Mr. Keller held the elective public office as Chancellor and Executive Vice President for University Development and Innovation at Leuphana University in Germany.

Prior to his public service work, he worked as President Asia for Bertelsmann Inc. in Shanghai, Seoul and Sydney after holding topmanagement positions with the media-group in Gütersloh, London and New York. Before, Holm Keller served a consultant with McKinsey & Company Inc., where he co-lead the development of the Firm's global Accelerator Practice. Earlier in his career, he held operative functions with ARD, ZDF and arte television.

Originally trained as a musical composer, Keller holds degrees from Vienna University and Harvard's Kennedy School of Government.

